Canopy Growth Corp
No SEC Form 4 filings for $CGC in the last 30 days.
See all $CGC insider activity →Canopy Growth (NASDAQ: CGC) says it has simplified operations, reduced expenses, exited BioSteel, and completed its MTL Cannabis acquisition. The company reported about $131.3M net cash at fiscal 2026 end (June 30) after a recapitalization. It cited 27% Q4 growth in Canadian medical cannabis revenue and 68% international medical growth, while noting ongoing losses and U.S. regulatory risk.
Canopy Growth (CGC) reported Q1 2027 adjusted gross margin of 31%, up from 25% a year earlier, and said it targets mid-30% adjusted gross margins near term. Management cited cultivation yield and quality improvements and full integration of MTL Cannabis. It also said international cannabis net revenue rose 10% YoY, Poland sales grew, and UK flower shipments are expected in the second half of fiscal 2027. Synergies from MTL are targeting $10M run rate within 18 months.
Canopy Growth (CGC) says shareholders will vote at its Sept. 25, 2026 annual general and special meeting on seven items, including electing five directors, appointing MNP LLP as auditor, and approving a potential 1-for-5 to 1-for-15 share consolidation. The proxy also covers incentive plan renewals and advisory say-on-pay and say-on-frequency votes. Constellation Brands holds about 5.8% on an as-converted basis.
Over the past 7 days, alphai's AI scored 8 news stories mentioning CGC (Canopy Growth Corp). Coverage has skewed bullish: 5 bullish, 2 neutral, and 1 bearish.
Recent CGC coverage spans earnings, corporate actions and financial news.
Narrative shift toward a potentially investable turnaround, but the piece is still framed as not yet consistently profitable.
Management provided a concrete margin trajectory (31% adjusted gross margin this quarter, targeting mid-30% near term) plus timing for cultivation yield benefits (end of Q2 into Q3).
If approved and later implemented, the consolidation could change per-share pricing, liquidity, and investor perception, while fractional shares would be cancelled for no consideration.
Auditor change plus prior restatement and an adverse internal-control opinion increases accounting and governance risk, which can pressure valuation and raise diligence expectations.
Q1 earnings call highlights point to improving gross margins and operating leverage, with a clear path to EBITDA profitability in fiscal 2027.
alphai scores every news story that mentions CGC with an AI model for sentiment and relevance, and aggregates insider trades from Canopy Growth Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Canopy Growth (NASDAQ: CGC) says it has simplified operations, reduced expenses, exited BioSteel, and completed its MTL Cannabis acquisition. The company reported about $131.3M net cash at fiscal 2026 end (June 30) after a recapitalization. It cited 27% Q4 growth in Canadian medical cannabis revenue and 68% international medical growth, while noting ongoing losses and U.S. regulatory risk.
7 min readCanopy Growth (CGC) reported Q1 2027 adjusted gross margin of 31%, up from 25% a year earlier, and said it targets mid-30% adjusted gross margins near term. Management cited cultivation yield and quality improvements and full integration of MTL Cannabis. It also said international cannabis net revenue rose 10% YoY, Poland sales grew, and UK flower shipments are expected in the second half of fiscal 2027. Synergies from MTL are targeting $10M run rate within 18 months.
4 min readCanopy Growth (CGC) says shareholders will vote at its Sept. 25, 2026 annual general and special meeting on seven items, including electing five directors, appointing MNP LLP as auditor, and approving a potential 1-for-5 to 1-for-15 share consolidation. The proxy also covers incentive plan renewals and advisory say-on-pay and say-on-frequency votes. Constellation Brands holds about 5.8% on an as-converted basis.
6 min readCanopy Growth (CGC) filed an 8-K saying its independent auditor PKF O’Connor Davies, LLP resigned effective Aug. 7, 2026 due to strategic changes in serving the cannabis sector. The filing notes no disagreements on accounting or disclosures, but cites an adverse internal-control opinion for FY ended Mar. 31, 2026 and going-concern language in FY 2025.
4 min readCanopy Growth (NASDAQ:CGC) reported Q1 Canadian adult-use revenue up 10% to C$29.7 million and international revenue up 10% year over year, citing growth in Poland. Adjusted consolidated gross margin rose to 31% from 25% a year earlier. Storz & Bickel revenue rose 6% to C$16.1 million. Canopy said it expects UK flower shipments to start imminently, with revenue in 2H FY2027.
6 min readCanopy Growth reported fiscal Q1 results, with adjusted EPS loss of 5.8 cents versus a 7.76-cent loss expected, and revenue of $82.2 million versus $82.29 million forecast. Net revenue rose 13% YoY to CAD 81.2 million, adjusted gross margin improved to 31%, and adjusted EBITDA loss narrowed to CAD 3.2 million. Shares rose 3.01% to $1.37 premarket.
6 min readCanopy Growth (TSX: WEED, Nasdaq: CGC) reported Q1 FY2027 results for the three months ended June 30, 2026. Consolidated net revenue rose 13% to C$81.2M, with growth across Canada medical, Canada adult-use, and international. Adjusted gross margin increased to 31% and the adjusted EBITDA loss narrowed 59% to C$3.2M. Free cash outflow widened to C$25.7M.
6 min readCanopy Growth Corp (CGC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cgc-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Canopy Growth Reports First Quarter Fiscal Year 2027 Financial Results; Delivers 13% Net Revenue Growth with Contributions from All Businesses Net revenue growth of 22% in Canada medical cannabis, 10% in Canada adult-use canna
6 min readCanopy Growth Corporation (TSX: WEED, Nasdaq: CGC) will report first quarter fiscal 2027 results for the period ended June 30, 2026 before market open on Aug. 7, 2026. The company plans an audio webcast the same day at 10:00 a.m. ET with CEO Luc Mongeau and CFO Tom Stewart.
1 min readTrump’s executive order directed the DEA to reschedule marijuana from Schedule I to Schedule III, enacted in April by acting Attorney General Todd Blanche. The change applies to medical cannabis, potentially removing IRS Section 280E limits on deductions. The article says Canopy Growth and Tilray are only incrementally affected, while Green Thumb’s medical impact is unclear due to limited segment disclosure.
7 min read
